Literature DB >> 15825532

Complications of intravitreal injection of triamcinolone acetonide.

Abdullah Ozkiriş1, Kuddusi Erkiliç.   

Abstract

BACKGROUND: Intravitreal injection of triamcinolone acetonide appears to be a promising treatment for a variety of proliferative, edematous, neovascular and inflammatory ocular disorders. Reported complications include intraocular pressure (IOP) elevation, cataract formation, retinal detachment, vitreous hemorrhage and endophthalmitis. The purpose of this investigation was to report the complications of intravitreal triamcinolone injection that may be attributable to the injection procedure or to the corticosteroid suspension.
METHODS: A total of 212 eyes of 180 patients who underwent intravitreal triamcinolone acetonide injection for various indications were enrolled. All patients received 8 mg/0.2 mL of triamcinolone. A total of 270 injections were performed by the same surgeon under topical anesthesia. The patients were followed for a mean of 9.2 months. Complications related to the injection procedure and to the corticosteroid were recorded.
RESULTS: The most common complication encountered during follow-up was transient elevation of the IOP above 21 mm Hg (44 eyes [20.8%]). The average IOP rose by 28.5%, 38.2%, 16.7% and 4.2% from baseline at 1, 3, 6 and 9 months respectively. The mean IOP values at 1, 3 and 6 months were statistically significantly higher than the mean preinjection value (p < 0.001). Fourteen eyes (6.6%) had cataract progression and underwent cataract surgery with intraocular lens implantation. Endophthalmitis developed in one eye (0.5%); the patient underwent vitrectomy with silicone oil injection. Pseudoendophthalmitis occurred in one eye (0.5%), and pseudohypopyon was observed in two eyes (0.9%).
INTERPRETATION: Intravitreal triamcinolone injection was effective in a variety of ocular disorders. Patients should be monitored closely given the potential for complications of the injection procedure or the corticosteroid suspension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15825532     DOI: 10.1016/S0008-4182(05)80119-X

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  36 in total

1.  Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye.

Authors:  Samirkumar R Patel; Damian E Berezovsky; Bernard E McCarey; Vladimir Zarnitsyn; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-01       Impact factor: 4.799

Review 2.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

3.  Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease.

Authors:  Leyla Suna Atmaca; F Nilüfer Yalçindağ; Ozden Ozdemir
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-17       Impact factor: 3.117

4.  Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

Authors:  Rajendra S Kadam; Narayan P S Cheruvu; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

5.  Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Adv Healthc Mater       Date:  2014-03-20       Impact factor: 9.933

6.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

7.  Use of systemic steroid after successful macular surgery in eyes with epiretinal membrane: a randomized, controlled clinical study.

Authors:  M Ritter; S Sacu; G Matt; R Dunavölgyi; W Bühl; C Prünte; U Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2011-09-02       Impact factor: 3.775

8.  Mini drug pump for ophthalmic use.

Authors:  Saloomeh Saati; Ronalee Lo; Po-Ying Li; Ellis Meng; Rohit Varma; Mark S Humayun
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

9.  Effect of posterior sub-tenon triamcinolone in macular edema due to non-ischemic vein occlusions.

Authors:  Murali Mohan Gurram
Journal:  J Clin Diagn Res       Date:  2013-09-13

10.  Management of ocular complications of Vogt-Koyanagi-Harada syndrome.

Authors:  Irfan Perente; Canan Asli Utine; Hanefi Cakir; Vedat Kaya; Ilknur Tugal Tutkun; Omer Faruk Yilmaz
Journal:  Int Ophthalmol       Date:  2007-10-19       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.